company background image
GKOS

Glaukos NYSE:GKOS Stock Report

Last Price

US$48.04

Market Cap

US$2.3b

7D

-1.0%

1Y

-6.9%

Updated

29 Jan, 2023

Data

Company Financials +

GKOS Stock Overview

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

GKOS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Glaukos Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Glaukos
Historical stock prices
Current Share PriceUS$48.04
52 Week HighUS$64.49
52 Week LowUS$33.33
Beta1.2
1 Month Change9.98%
3 Month Change-14.32%
1 Year Change-6.88%
3 Year Change-14.60%
5 Year Change60.62%
Change since IPO53.88%

Recent News & Updates

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Recent updates

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Mar 14
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Nov 29
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Aug 15
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

When Should You Buy Glaukos Corporation (NYSE:GKOS)?

Jun 23
When Should You Buy Glaukos Corporation (NYSE:GKOS)?

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 27
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Apr 30
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of Glaukos Corporation (NYSE:GKOS)

Mar 30
Calculating The Intrinsic Value Of Glaukos Corporation (NYSE:GKOS)

At US$89.02, Is It Time To Put Glaukos Corporation (NYSE:GKOS) On Your Watch List?

Mar 04
At US$89.02, Is It Time To Put Glaukos Corporation (NYSE:GKOS) On Your Watch List?

Glaukos' (NYSE:GKOS) Wonderful 524% Share Price Increase Shows How Capitalism Can Build Wealth

Feb 06
Glaukos' (NYSE:GKOS) Wonderful 524% Share Price Increase Shows How Capitalism Can Build Wealth

Shareholder Returns

GKOSUS Medical EquipmentUS Market
7D-1.0%-0.2%2.8%
1Y-6.9%-9.7%-9.2%

Return vs Industry: GKOS exceeded the US Medical Equipment industry which returned -9.7% over the past year.

Return vs Market: GKOS exceeded the US Market which returned -9.2% over the past year.

Price Volatility

Is GKOS's price volatile compared to industry and market?
GKOS volatility
GKOS Average Weekly Movement5.7%
Medical Equipment Industry Average Movement8.8%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: GKOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: GKOS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998727Tom Burnshttps://www.glaukos.com

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication.

Glaukos Corporation Fundamentals Summary

How do Glaukos's earnings and revenue compare to its market cap?
GKOS fundamental statistics
Market CapUS$2.29b
Earnings (TTM)-US$89.61m
Revenue (TTM)US$284.88m

8.0x

P/S Ratio

-25.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GKOS income statement (TTM)
RevenueUS$284.88m
Cost of RevenueUS$68.62m
Gross ProfitUS$216.25m
Other ExpensesUS$305.86m
Earnings-US$89.61m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.88
Gross Margin75.91%
Net Profit Margin-31.45%
Debt/Equity Ratio51.2%

How did GKOS perform over the long term?

See historical performance and comparison